CROWN-MVNCT07798726
TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Not specified → Not applicable Show 10 more changesShow less
- Primary endpoint(s) modified
- Sponsor changed: [Redacted] to Abbott Medical Devices
- Trial status changed: Withheld → Recruiting
- Enrollment changed: None → 565
- Interventions modified
- Trial arms changed: 0 → 2
- Primary completion date: Dec 31, 2031
- Study completion date: Dec 31, 2035
- Start date: Oct 21, 2026
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Primary Effectiveness Endpoint
Timeframe: 12 months post index procedure.
Primary Safety Endpoint
Timeframe: 30 days post index procedure
Secondary (3)
Change in mitral regurgitation severity from baseline as assessed by the echocardiography core laboratory.
Change in Quality of Life from baseline as measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score
Change in the New York Heart Association Functional Classification of at least one grade from baseline.
Arms and interventions
Mitral Regurgitation CohortExperimental
Inclusive of subjects who have moderate-to-severe or severe Mitral Regurgitation
Mitral Annular Calcification (MAC) CohortExperimental
Inclusive of subjects with mitral valve dysfunction associated with MAC
Devices: Cephea Mitral Valve System
Sites
1 site in 1 country
- Ascension Via Christi Hospitals WichitaWichita, Kansas, United States